drugset / Trial / NCT00200447

An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)

NCT00200447

Phase 2 Completed 3 enrolled Molecular NeuroImaging
RandomizedCrossoverOpen-labelTreatment

Summary

This study conducted to more fully evaluate the way that carbidopa/levodopa and entacapone may work in the brain. This research study uses \[123I\]-IBZM and dynamic SPECT imaging to determine the amount and the duration of dopamine release from specific regions in the brain after treatment with either the combination of carbidopa/levodopa or the combination of carbidopa/levodopa/entacapone.

Timeline

Start
2004-03
Primary completion
2004-09
Completion
2004-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 37.5 mg Oral
Subject Carbidopa Unknown 50 mg Oral
Subject Entacapone Small molecule 200 mg Oral
Subject Levodopa Small molecule 150 mg Oral
Subject Levodopa Small molecule 250 mg Oral

Indications